Your browser is no longer supported. Please, upgrade your browser.
Settings
AMGN Amgen Inc. daily Stock Chart
AMGN [NASD]
Amgen Inc.
IndexS&P 500 P/E15.99 EPS (ttm)9.07 Insider Own0.10% Shs Outstand754.33M Perf Week-5.04%
Market Cap109.41B Forward P/E12.00 EPS next Y12.09 Insider Trans-0.26% Shs Float753.62M Perf Month-7.45%
Income6.94B PEG1.99 EPS next Q2.59 Inst Own82.00% Short Float1.20% Perf Quarter-9.95%
Sales21.66B P/S5.05 EPS this Y35.20% Inst Trans-0.10% Short Ratio2.48 Perf Half Y-13.68%
Book/sh37.25 P/B3.89 EPS next Y12.19% ROA9.80% Target Price184.63 Perf Year-3.53%
Cash/sh41.60 P/C3.49 EPS next 5Y8.02% ROE25.20% 52W Range129.43 - 180.06 Perf YTD-10.65%
Dividend4.00 P/FCF- EPS past 5Y13.60% ROI12.50% 52W High-21.71% Beta0.84
Dividend %2.76% Quick Ratio4.20 Sales past 5Y7.60% Gross Margin80.50% 52W Low8.90% ATR5.05
Employees17900 Current Ratio4.40 Sales Q/Q3.80% Oper. Margin39.10% RSI (14)33.57 Volatility2.77% 3.71%
OptionableYes Debt/Eq1.12 EPS Q/Q41.90% Profit Margin32.00% Rel Volume1.15 Prev Close145.04
ShortableYes LT Debt/Eq1.04 EarningsJan 28 AMC Payout34.50% Avg Volume3.64M Price140.96
Recom2.50 SMA20-6.70% SMA50-10.02% SMA200-9.85% Volume2,620,907 Change-2.81%
Feb-08-16Reiterated Argus Buy $202 → $185
Jan-20-16Initiated Credit Suisse Outperform $205
Dec-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-04-15Initiated Wells Fargo Market Perform
Oct-29-15Reiterated UBS Buy $168 → $180
Sep-01-15Initiated Raymond James Mkt Perform
Jul-31-15Reiterated RBC Capital Mkts Outperform $185 → $190
Jul-31-15Reiterated Deutsche Bank Buy $192 → $195
Jul-31-15Reiterated Barclays Equal Weight $180 → $185
May-28-15Reiterated Deutsche Bank Buy $200 → $192
Apr-22-15Reiterated UBS Buy $175 → $185
Apr-22-15Reiterated RBC Capital Mkts Outperform $178 → $185
Oct-29-14Reiterated Argus Buy $140 → $185
Oct-28-14Reiterated RBC Capital Mkts Outperform $150 → $165
Sep-08-14Reiterated RBC Capital Mkts Outperform $138 → $150
Aug-04-14Reiterated Argus Buy $135 → $140
Jul-30-14Reiterated RBC Capital Mkts Outperform $125 → $138
Jul-18-14Reiterated Deutsche Bank Buy $144 → $149
Apr-23-14Reiterated Oppenheimer Perform $121 → $122
Mar-21-14Reiterated Barclays Equal Weight $115 → $130
Feb-08-16 11:30AM  Regeneron: It's the Eylea Outlook That Matters at Barrons.com
10:11AM  UK cost agency rebuffs Sanofi cholesterol drug but backs Amgen's Reuters
Feb-07-16 05:54PM  Drug Industry Launches Ad Effort Aimed at Lawmakers at The Wall Street Journal
07:20AM  Biogen Inc. Takes Aim at Johnson & Johnson at Motley Fool
Feb-06-16 07:06AM  Eli Lilly and Co.s 4Q15 Business Segment Performance
Feb-05-16 05:05PM  Amgen To Present At The Leerink Partners 5th Annual Global Healthcare Conference PR Newswire
04:45PM  LinkedIn Downgraded; Biotechs Initiated; Tableau PT Cut
04:25PM  Amgen's Blincyto and Repatha Positive in Phase III Studies
10:32AM  Leerink Is Back On Board The Biotech Train
08:50AM  Generous Dividend Yields And Long Term Optimism: Are Amgen And Apple Smart Investments? at Forbes
07:46AM  [$$] 3 Earnings Dynamos That Are Lighting Up the Street at Barrons.com
Feb-04-16 04:16PM  Phase 3 Study of BLINCYTO® (Blinatumomab) Met Primary Endpoint Of Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia PR Newswire
04:05PM  Workday Snatches Amgen Exec as First CIO at The Wall Street Journal
04:00PM  Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha® (Evolocumab) In Statin-Intolerant Patients With High Cholesterol PR Newswire
02:29PM  Its Time to Buy This Biotech Gem
09:10AM  7 Cash-Rich Stocks to Buy Now at Kiplinger
08:45AM  Behind the Curtain: Factors of Growth - Analyst Notes on Exxon Mobil, Southern Co., Visa and Amgen Accesswire
05:19AM  [$$] Borrowers return to eurozone bond markets at Financial Times
Feb-03-16 12:20PM  Workday Hires New CIO Diana McKenzie From Amgen at Forbes
10:25AM  Workday taps Amgen exec Diana McKenzie for CIO at ZDNet
10:19AM  Will 2016 Be Amgen Inc.'s Best Year Yet? at Motley Fool
10:08AM  How Much Does Biogen Spend on Research and Development?
08:10AM  Insight into the Performance of Interferon and Other Products
Feb-02-16 06:03PM  Why NantKwest Shares Fell 41% in January at Motley Fool
04:33PM  Gilead: 4Q EPS, Revenue Beat at Barrons.com
12:54PM  Amgen, Inc. Earnings Analysis: Q4, 2015 By the Numbers
Feb-01-16 05:01PM  3 Biotech Stocks You Don't Have to Babysit at Motley Fool
10:10AM  Company News for February 01, 2016
09:50AM  The 4 Largest Biotech Stocks Are Cheaper Than S&P 500 at 24/7 Wall St.
08:45AM  Super Stock Review Amgen: IBD Investing Show Excerpt
Jan-30-16 03:34PM  AbbVie: There Ain't No Stinkin' Biosimilar Threat at Motley Fool
12:58PM  Facebook, Amazon A Tale Of 2 Leaders: IBD Investing Show
11:00AM  Where to Invest Money in 2016: 7 Great Ideas at Motley Fool
08:05AM  Vertex Will Focus on Cystic Fibrosis Market in 2016
Jan-29-16 04:06PM  Regeneron Continues to Trade at Premium
01:17PM  Feeling Woozy About Amgen's Future
11:49AM  AbbVie Reports Mixed Q4 As Merck Launches Rival HCV Treatment
09:39AM  Why Amgen's Earnings Weren't Good Enough at Barrons.com
09:32AM  Amgen's Q4 Crushed Estimates and Answered 3 Important Questions in the Process at Motley Fool
09:30AM  The Zacks Analyst Blog Highlights: Amazon.com, Microsoft, Visa, Skyworks Solutions and Amgen
09:05AM  Amgen Tops on Q4 Earnings & Revenues, Ups 2016 Outlook
08:39AM  Maybe Some Good News For A Big Biotech ETF
08:30AM  Nearly all of our medical research is wrong
08:09AM  Early movers: XRX, WHR, AAL, CL, PSX, AMZN & more at CNBC
03:49AM  Edited Transcript of AMGN earnings conference call or presentation 28-Jan-16 10:00pm GMT
Jan-28-16 07:46PM  Amgen trounces Street views with 39 pct. jump in 4Q profit
06:39PM  Amgen 4th quarter profit tops Street; raises 2016 forecast
06:26PM  Amgen Tour offers postcard views of California -- and economic benefits at bizjournals.com
06:13PM  Q4 Pedal to the Metal: AMZN, MSFT, V & More
06:00PM  Amgen, Bristol-Myers Beat Q4 Views Amid Drug-Stock Bloodbath
05:44PM  Amgen (AMGN) Beats Q4 Earnings, Revenue Estimates
05:06PM  What Do Analysts Expect from Regeneron in 2016?
05:00PM  Amgen Inc Earnings Call scheduled for 5:00 pm ET today
04:52PM  Why Amazon, Microsoft, Xerox And Amgen Are Moving After-Hours
04:34PM  Earnings Recap For January 28
04:32PM  Amgen (AMGN) Stock Gaining in After-Hours Trading on Earnings Beat at TheStreet
04:31PM  Amgen Posts Handy Beat on Estimates and Guidance
04:25PM  Amgen's 2015 Revenues Increased 8 Percent To $21.7 Billion And Adjusted Earnings Per Share (EPS) Increased 19 Percent To $10.38 at noodls
04:15PM  AMGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:07PM  Amgen 4th quarter profit tops Street estimates as costs fall
04:06PM  Amgen Tops Fourth-Quarter Profit Estimates, Raises 2016 Guidance at Bloomberg
04:01PM  [$$] Amgen Profit Rises 39%; 2016 Outlook Raised at The Wall Street Journal
04:00PM  Amgen's 2015 Revenues Increased 8 Percent To $21.7 Billion And Adjusted Earnings Per Share (EPS) Increased 19 Percent To $10.38 PR Newswire
03:40PM  Celgene Corporation Looks Forward at Motley Fool
02:05PM  Bargains Anyone? Big-Cap Biotech Stocks Plumb Lowest Valuations in 10 Years at Barrons.com
12:05PM  Top Biotechs for 2016 at Motley Fool
08:35AM  Short Sellers Increase Bets in Major Biotechs at 24/7 Wall St.
07:07AM  Q4 2015 Amgen Inc Earnings Release - After Market Close
Jan-27-16 02:35PM  Amgen's Biosimilar of AbbVie's Humira under FDA Review
12:31PM  What Can Investors Expect from Regenerons 4Q15 Earnings?
10:11AM  Regeneron: A Cut With 15% Upside? at Barrons.com
10:02AM  3 Key Numbers to Monitor When Amgen Reports Fourth-Quarter Results at Motley Fool
08:00AM  Equities Updates on Biotechnology -- Celldex Therapeutics, Amgen, Exelixis, and Ariad Pharma Accesswire
Jan-26-16 12:30PM  Will Amgen (AMGN) Continue with the Earnings Streak in Q4?
07:26AM  AbbVie in 4Q15: Analysts Project Strong Revenue Growth
Jan-25-16 05:59PM  3 Reasons to Be Bearish on CVS Health at Motley Fool
05:47PM  FDA Accepts Amgen's Biosimilar Biologics License Application For ABP 501 at noodls
05:19PM  FDA Accepts Amgen's Biosimilar Biologics License Application For ABP 501 PR Newswire
04:45PM  Amgen Presents Encouraging Phase III Data on Vectibix
04:42PM  Relypsa Results Surprise Wall Street
04:17PM  Amgen Announces Webcast of 2015 Fourth Quarter and Full Year Financial Results at noodls
04:02PM  Amgen Announces Webcast of 2015 Fourth Quarter and Full Year Financial Results PR Newswire
01:56PM  Supreme Court Grants Slight Reprieve To Company Stock In Retirement Accounts at Forbes
01:03PM  Biotech String: Editas IPO Terms, Rooting for Shkreli in DC at TheStreet
11:50AM  5 Big-Cap Drugmakers Reporting Q4 Earnings This Week; J&J First
10:07AM  Celgenes Valuation Is Higher Than Its Peers
09:51AM  Regeneron: Sell on Patent Fears, Chardan Says at Barrons.com
09:49AM  U.S. top court rules for Amgen over employee lawsuit Reuters
07:45AM  Investors look to Biogen earnings this week to pull sector out of slump at bizjournals.com
05:30AM  Draghi and a Counter Trend Rally in Oil Rescue the Markets
Jan-24-16 04:55PM  Big Earnings Expectations For Big Biotech
Jan-23-16 02:00PM  Last Week's Best Healthcare ETF at Motley Fool
01:00PM  Vectibix® (panitumumab) And Best Supportive Care Improves Overall Survival Compared To Best Supportive Care In Chemorefractory KRAS And RAS Wild-Type Metastatic Colorectal Cancer PR Newswire
Jan-22-16 04:30PM  Amgen Kyprolis' Label Expanded, Repatha Approved in Japan
04:05PM  AbbVie Advanced Its Mid- and Late-Stage Research Pipeline in 3Q15
08:07AM  Revlimid Continues to Drive Celgenes Revenue
01:00AM  Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol PR Newswire
Jan-21-16 05:23PM  FDA gives full approval to Amgen blood cancer drug Reuters
04:32PM  FDA Approves New Kyprolis® (Carfilzomib) Combination Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma PR Newswire
08:38AM  5 Burning Questions We Want Answered When Johnson & Johnson Reports Its Q4 Results at Motley Fool
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company's principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. Its principal products also comprise EPOGEN for the treatment of dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis. The company's other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with Xencor, Inc., AstraZeneca Plc, Takeda Pharmaceutical Company Limited, UCB, Novartis AG, Bayer HealthCare Pharmaceuticals Inc., Merck & Co. Inc, and Biocartis Group NV. The company was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
de Carbonnel FrancoisDirectorAug 31Sale153.845,000769,19215,150Sep 02 07:46 PM
Hassan FredDirectorAug 19Buy166.633,010501,5623,582Aug 20 05:58 PM
PELHAM JUDITH CDirectorJul 31Sale180.405,035908,31411,890Aug 04 06:31 PM
Patton Cynthia MSVP & CCOJun 02Sale157.064,530711,48216,571Jun 03 07:16 PM
Balachandran MadhavanEVP, OperationsMay 07Option Exercise55.7221,7501,211,94855,144May 11 04:56 PM
Balachandran MadhavanEVP, OperationsMay 07Sale157.8721,7503,433,69533,394May 11 04:56 PM
Tross Stuart ASVP, Human ResourcesApr 23Sale169.313,012509,96421,923Apr 24 04:53 PM
Harper Sean EEVP, Research & DevelopmentApr 22Sale171.5828,0004,804,24047,920Apr 23 05:04 PM
Tross Stuart ASVP, Human ResourcesMar 03Sale157.744,415696,42720,237Mar 04 08:25 PM
BALTIMORE DAVIDDirectorMar 02Sale158.763,647579,01131,159Mar 03 08:55 PM
BALTIMORE DAVIDDirectorFeb 19Option Exercise42.135,000210,65036,159Feb 23 04:13 PM
Bradway Robert AChairman, CEO and PresidentFeb 11Option Exercise42.1384,0003,538,920258,641Feb 12 09:09 PM
Bradway Robert AChairman, CEO and PresidentFeb 11Sale152.6922,0003,359,116218,102Feb 12 09:09 PM